- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05827835
CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
April 11, 2023 updated by: He Huang, Zhejiang University
A Study to Evaluate the Efficacy and Safety of CD7CAR-T Bridging to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed CD7 Positive Malignant Hematologic Diseases
This is a single-arm, open-label, single-center, phase I study.
The primary objective is to evaluate the safety of CD7 CAR-T Bridging to allo-HSCT therapy for patients with CD7-positive relapsed or refractory Malignant Hematologic Diseases
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: He Huang, MD
- Phone Number: +86-0571-87236476
- Email: hehuangyu@126.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Recruiting
- The first affiliated hospital of medical college of zhejiang university
-
Contact:
- Yongxian Hu, MD
- Phone Number: +8615957162012
- Email: huyongxian2000@aliyun.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form (ICF)
- Male or female, 18-75 years old
- Anticipated survival time more than 12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2
- According to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Lymphocytic Leukemia and Acute Myeloid Leukemia (2016. v1), patients diagnosed as CD7+ALL and AML
- Consistent with r/r CD7+acute leukemia diagnosis, including any of the following conditions
- a. No CR after standard chemotherapy
- b. The first induction reaches CR, but CR ≤ 12 months
- c. Patients with r/r CD7+acute leukemia have not responded to the first or multiple remedial treatments
- d. Multiple recurrences
- Philadelphia chromosome negative (Ph -) subjects; Or cannot tolerate tyrosine kinase inhibitor (TKI) treatment; Or Philadelphia chromosome positive (Ph+) subjects who did not respond to both TKI treatments
- Normal lung function, oxygen saturation greater than 92% without oxygen inhalation
- The blood biochemical test results are consistent with the following results
- a. (AST) and (ALT) ≤ 2.5 × (ULN)
- b. Total bilirubin ≤ 1.5 × ULN
- c. 24-hour serum creatinine clearance ≥ 30 mL/min
- d. Lipase and amylase ≤ 2 × ULN
- Fertility capable men and women of childbearing age must agree to use effective contraception starting with the signing of an informed consent form until within 2 years after the use of the study drug. Women of reproductive age include pre menopausal women and women within 2 years after menopause. The blood pregnancy test for women of reproductive age must be negative at screening
Exclusion Criteria:
- Patients with the history of epilepsy or other CNS disease
- Pregnant or breastfeeding
- Active infection with no cure
- Patients with prolonged QT interval time or severe heart disease
- Have experienced hypersensitivity or intolerance to any drug used in this study
- Patients who received anticancer chemotherapy or other drug treatment within 2 weeks before screening
- Previous malignant tumors that require treatment or have evidence of recurrence within the previous 5 years of screening
- Clinically significant central nervous system lesions such as seizures, cerebral vascular ischemia/hemorrhage, dementia, cerebellar disease, psychosis, active central nervous system involvement, or cancerous meningitis
- In the past 2 years, terminal organ damage caused by autoimmune diseases (such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) or the need for systematic application of immunosuppressive or other systemic disease control drugs
- Severe active viral, bacterial, or uncontrolled systemic fungal infections; Genetic bleeding/coagulation disorders, a history of non-traumatic bleeding or thromboembolism, and other diseases that may increase the risk of bleeding
- Patients who received autologous hematopoietic stem cell transplantation (ASCT) within 8 weeks before screening, or who plan to undergo ASCT during this study
- Participated in clinical trials of other drugs within 4 weeks or 5 drug half-lives (T1/2) before screening
- Any situation that the researchers believe may increase the risk of patients or interfere with the test results.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Group
R/R CD7+Malignant Hematologic Diseases
|
CD7 CAR T cells treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and level of AE and SAE
Time Frame: Baseline up to 28 days after CD7 CAR T-cells infusion
|
Adverse events assessed according to NCI-CTCAE v5.0 criteria
|
Baseline up to 28 days after CD7 CAR T-cells infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: Month 6,12,18and 24
|
Assessment of PFS at Month 6,12,18and 24
|
Month 6,12,18and 24
|
CAR-T cell expression
Time Frame: Evaluate at 1, 2, 3, 4, 8,12,16, 20 and 24 weeks after CAR-T infusion
|
CAR-T cell expression in vivo
|
Evaluate at 1, 2, 3, 4, 8,12,16, 20 and 24 weeks after CAR-T infusion
|
CAR-T related cytokine expression
Time Frame: Evaluate at 1, 2, 3 and 4 weeks after CAR-T infusion
|
CAR-T related cytokine expression
|
Evaluate at 1, 2, 3 and 4 weeks after CAR-T infusion
|
Survival Rate (SR)
Time Frame: Evaluate at 6, 9, and 12 months
|
Survival Rate (SR)
|
Evaluate at 6, 9, and 12 months
|
Time-To-Progression(TTP)
Time Frame: Month 2,3,4,6,12,18and 24
|
Time from the beginning of treatment to the progression of the disease
|
Month 2,3,4,6,12,18and 24
|
Duration of remission,DOR
Time Frame: Up to 1 years after Treatment
|
The time from CR/CRi and PR to disease relapsed or death due to disease progression after CAR-T infusion
|
Up to 1 years after Treatment
|
Overall response rate,ORR
Time Frame: Evaluate at 4, 8, and 12 weeks after CAR-T infusion
|
The proportion of patients with CR (complete remission) /CRi (complete remission with incomplete blood count recovery); The proportion of patients with CR (complete response) /CRi (complete response with incomplete blood cell recovery) and PR (partial response).
|
Evaluate at 4, 8, and 12 weeks after CAR-T infusion
|
Clinical Benefit Rate(CBR)
Time Frame: Up to 24 weeks after Treatment
|
ORR+MR
|
Up to 24 weeks after Treatment
|
Disease Control Rate (DCR)
Time Frame: Up to 12 weeks after Treatment
|
CBR+SD
|
Up to 12 weeks after Treatment
|
Overall survival, OS
Time Frame: Up to 1 years after Treatment
|
The time from CAR-T infusion to death due to any cause
|
Up to 1 years after Treatment
|
Minimal Residual Disease
Time Frame: Up to 2 years after Treatment
|
MRD in CR and sCR patients
|
Up to 2 years after Treatment
|
Bone marrow transplantation STR
Time Frame: Evaluate at 4, 8,12,16 and 20 weeks after allogeneic hematopoietic stem cell transplantation
|
Monitoring the status of allogeneic hematopoietic stem cell transplantation using STR-PCR
|
Evaluate at 4, 8,12,16 and 20 weeks after allogeneic hematopoietic stem cell transplantation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
April 30, 2023
Primary Completion (Anticipated)
April 25, 2025
Study Completion (Anticipated)
April 25, 2025
Study Registration Dates
First Submitted
March 30, 2023
First Submitted That Met QC Criteria
April 11, 2023
First Posted (Actual)
April 25, 2023
Study Record Updates
Last Update Posted (Actual)
April 25, 2023
Last Update Submitted That Met QC Criteria
April 11, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TXB2022023
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
John M. BuattiNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedUterine Cervical Neoplasms | Prostatic Neoplasms | Rectal Neoplasms | Endometrial Neoplasms | Anus NeoplasmsUnited States
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
European Association for Endoscopic SurgeryWithdrawn
-
Moscow Clinical Scientific CenterRecruitingCecal Neoplasms | Colonic Neoplasms MalignantRussian Federation
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
GlaxoSmithKlineRecruitingColonic Neoplasms | Neoplasms, ColonUnited States, Finland, France, Italy, Japan, Netherlands, Norway, Spain, Taiwan, United Kingdom, Australia, Belgium, Brazil, Germany, Greece, Sweden, Turkey, Canada, Korea, Republic of, Argentina, Hungary, Estonia, Portugal, Mexico, Pa...
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
Clinical Trials on CD7 CAR-T cells injection
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingAutoimmune Diseases | Crohn Disease | Ulcerative Colitis | Dermatomyositis | Still DiseaseChina
-
Shenzhen University General HospitalRecruiting
-
iCell Gene TherapeuticsPeking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.RecruitingT-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic LymphomaChina
-
Bioceltech Therapeutics, Ltd.RecruitingT Cell Lymphoblastic LymphomaChina
-
Shanghai General Hospital, Shanghai Jiao Tong University...RecruitingAnaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | T-cell Acute Lymphoblastic Leukemia | T Lymphoblastic Leukemia/LymphomaChina
-
The First Affiliated Hospital of Soochow UniversityAffiliated Hospital of Jiangnan University; The Affiliated Nanjing Drum Tower... and other collaboratorsRecruiting
-
Shenzhen Geno-Immune Medical InstituteThe Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...RecruitingAcute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell LymphomaChina
-
Shenzhen Geno-Immune Medical InstituteRecruitingAcute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell LymphomaChina
-
Beijing GoBroad HospitalRecruitingAcute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic LeukemiaChina
-
Guangzhou Bio-gene Technology Co., LtdActive, not recruitingT-Cell Acute Lymphocytic LeukemiaChina